11 news items
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
RYTM
11 Jun 24
Population: The prescribing physician should periodically assess response to setmelanotide therapy. In growing children, the impact of weight
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
RYTM
3 Jun 24
Population: The prescribing physician should periodically assess response to setmelanotide therapy. In growing children, the impact of weight
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
RYTM
3 Jun 24
should periodically assess response to setmelanotide therapy. In growing children, the impact of weight loss on growth and maturation should
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
RYTM
22 May 24
. Pediatric Population: The prescribing physician should periodically assess response to setmelanotide therapy. In growing children
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
RYTM
6 May 24
setmelanotide. Pediatric Population: The prescribing physician should periodically assess response to setmelanotide
7kset1vz70g42 jtqb31ncygaciu8gz96bxfi7c8b
RYTM
29 Apr 24
the melanocortin-4 receptor (MC4R) pathway and is responsible for controlling physiological functions such as hunger and weight regulation. It most
q7xbsnlnmlieqcqspmdoi8 qq1l
RYTM
29 Apr 24
, which includes the melanocortin-4 receptor (MC4R) pathway and is responsible for controlling physiological functions such as hunger and weight
gv7sqh3
RYTM
26 Apr 24
their response to recent developments related to Rhythm Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state
w70q9uvhyu58g08xgdfcbz9fpi974apqfq86n
RYTM
24 Apr 24
periodically assess response to setmelanotide therapy. In growing children, the impact of weight loss on growth and maturation should be evaluated
nte2lvtl4acj3toi56jtmnb4k3ekdezsoawmphmjt
RYTM
16 Apr 24
and discontinue setmelanotide. Pediatric Population: The prescribing physician should periodically assess response to setmelanotide therapy
0whp035q25bnsjrfgorx tiyqbnszy6yy15p7xeg329quf6yp4o9n5k6
RYTM
10 Apr 24
Key Insights:
Action Taken: In response to dynamic market conditions and company
- Prev
- 1
- Next